precision
biosciences
present
upcoming
virtual
investor
conferences
october
durham
globe
newswire
precision
biosciences
nasdaq
dtil
clinical
stage
biotechnology
company
developing
allogeneic
car
vivo
gene
correction
therapies
genome
editing
platform
today
announced
participation
following
upcoming
virtual
investor
conferences
chardan
th
annual
genetic
medicines
conference
date
monday
october
time
et
date
monday
october
time
et
jefferies
cell
therapy
summit
date
october
time
pm
et
live
webcasts
presentation
accessible
company
website
investors
media
section
archived
replay
webcasts
available
approximately
days
following
presentations
precision
biosciences
inc
precision
biosciences
clinical
stage
biotechnology
company
dedicated
improving
life
dtil
novel
proprietary
genome
editing
platform
arcus
highly
specific
versatile
genome
editing
platform
designed
therapeutic
safety
delivery
control
mind
using
arcus
company
pipeline
consists
multiple
car
immunotherapy
clinical
candidates
several
vivo
gene
correction
therapy
candidates
cure
genetic
infectious
diseases
adequate
treatments
exist
information
precision
biosciences
please
visit
investor
media
contact
maurissa
messier
senior
director
corporate
communications
josh
rappaport
stern
investor
relations
